Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Options
Three new option listings and two option delistings on June 9th » 08:30
06/09/22
06/09
08:30
06/09/22
08:30
META

Meta Platforms

$196.61 /

+1.02 (+0.52%)

, FANH

Fanhua

$4.60 /

-0.18 (-3.77%)

, FB

Meta Platforms

/

+

, RLGY

Realogy

/

+

New option listings for…

New option listings for June 9th include HOUS Stock (HOUS), META Stock (META), and Fanhua (FANH). Option delistings effective June 9th include Facebook (FB) and Realogy (RLGY).

ShowHide Related Items >><<
RLGY Realogy
/

+

META Meta Platforms
$196.61 /

+1.02 (+0.52%)

FB Meta Platforms
/

+

FANH Fanhua
$4.60 /

-0.18 (-3.77%)

META Meta Platforms
$196.61 /

+1.02 (+0.52%)

05/10/22 BMO Capital
Yelp price target lowered to $37 from $42 at BMO Capital
04/06/22 DA Davidson
System1 price target raised to $26 from $23 at DA Davidson
03/25/22 UBS
Meta Platforms newsfeed changes and Reelz to drive higher monetization, says UBS
FANH Fanhua
$4.60 /

-0.18 (-3.77%)

FB Meta Platforms
/

+

06/08/22 Piper Sandler
Piper sees pockets of optimism but also privacy headwinds for Meta Platforms
06/02/22 Citi
Meta revenue growth should pick-up in second half, says Citi
06/02/22 Oppenheimer
COO departure not affecting long-term view on Meta shares, says Oppenheimer
06/02/22 Mizuho
Meta Platforms' Sheryl Sandberg difficult to replace, says Mizuho
RLGY Realogy
/

+

02/22/22 Barclays
Realogy price target raised to $19 from $17 at Barclays
12/20/21 JPMorgan
Realogy upgraded ton positive housing backdrop at JPMorgan
12/20/21 JPMorgan
Realogy upgraded to Overweight from Neutral at JPMorgan
08/31/21 Keefe Bruyette
Realogy upgraded to Outperform from Market Perform at Keefe Bruyette
RLGY Realogy
/

+

FB Meta Platforms
/

+

RLGY Realogy
/

+

META Meta Platforms
$196.61 /

+1.02 (+0.52%)

FB Meta Platforms
/

+

RLGY Realogy
/

+

META Meta Platforms
$196.61 /

+1.02 (+0.52%)

FB Meta Platforms
/

+

META Meta Platforms
$196.61 /

+1.02 (+0.52%)

FB Meta Platforms
/

+

FANH Fanhua
$4.60 /

-0.18 (-3.77%)

Options
Twelve new option listings and one option delisting on June 8th » 08:30
06/08/22
06/08
08:30
06/08/22
08:30
ERAS

Erasca

$5.72 /

+0.23 (+4.19%)

, DNAY

Codex DNA

$3.65 /

+0.05 (+1.39%)

, AIP

Arteris IP

$8.98 /

-0.045 (-0.50%)

, CMAX

CareMax

$5.17 /

-0.38 (-6.85%)

, PRCT

Procept BioRobotics

$38.81 /

-1.29 (-3.22%)

, CTKB

Cytek Biosciences

$10.95 /

+0.19 (+1.77%)

, CVRX

CVRx

$6.76 /

+0.675 (+11.10%)

, FDT

Federal Trust Corporation

$56.23 /

+0.53 (+0.95%)

, FANH

Fanhua

$4.78 /

+0.08 (+1.70%)

New option listings for…

New option listings for June 8th include BAD ETF (BAD), DJIA ETF (DJIA), Erasca Inc (ERAS), Codex DNA Inc (DNAY), Arteris Inc (AIP), CareMax Inc (Class A Stock) (CMAX), Deutsche X trackers MSCI All China Equity ETF (CN), Procept Biorobotics Corp (PRCT), Cytek Biosciences Inc (CTKB), CVRx Inc (CVRX), First Trust Developed Markets ex US AlphaDEX Fund (FDT), and TILL ETF (TILL). Option delistings effective June 8th include Fanhua (FANH).

ShowHide Related Items >><<
PRCT Procept BioRobotics
$38.81 /

-1.29 (-3.22%)

FANH Fanhua
$4.78 /

+0.08 (+1.70%)

ERAS Erasca
$5.72 /

+0.23 (+4.19%)

DNAY Codex DNA
$3.65 /

+0.05 (+1.39%)

CVRX CVRx
$6.76 /

+0.675 (+11.10%)

CTKB Cytek Biosciences
$10.95 /

+0.19 (+1.77%)

CMAX CareMax
$5.17 /

-0.38 (-6.85%)

AIP Arteris IP
$8.98 /

-0.045 (-0.50%)

ERAS Erasca
$5.72 /

+0.23 (+4.19%)

01/03/22 Guggenheim
Erasca price target lowered to $20 from $25 at Guggenheim
08/10/21
Fly Intel: Top five analyst initiations
08/10/21 Evercore ISI
Erasca initiated with an Outperform at Evercore ISI
08/10/21 JPMorgan
Erasca initiated with an Overweight at JPMorgan
DNAY Codex DNA
$3.65 /

+0.05 (+1.39%)

03/28/22 KeyBanc
Codex DNA price target lowered to $8 from $30 at KeyBanc
03/02/22 Cowen
Codex DNA assumed with an Outperform at Cowen
12/30/21 KeyBanc
Pfizer deal provides key validation of Codex DNA's technology, says KeyBanc
10/14/21 Cowen
Codex DNA coverage transferred at Cowen
AIP Arteris IP
$8.98 /

-0.045 (-0.50%)

06/08/22
Baird to hold a conference
05/11/22 Cowen
Arteris IP price target lowered to $19 from $23 at Cowen
05/11/22 BMO Capital
Arteris IP price target lowered to $15 from $20 at BMO Capital
CMAX CareMax
$5.17 /

-0.38 (-6.85%)

05/11/22 Cowen
CareMax price target lowered to $8 from $11 at Cowen
01/07/22 UBS
CareMax initiated with a Buy at UBS
12/01/21 Piper Sandler
Piper Sandler remains buyer of CareMax after management meeting
11/15/21 Piper Sandler
Piper remains buyer of CareMax, likes share setup into Q4
PRCT Procept BioRobotics
$38.81 /

-1.29 (-3.22%)

03/09/22 Guggenheim
Procept BioRobotics price target lowered to $40 from $55 at Guggenheim
10/11/21 Cowen
Procept BioRobotics initiated with Outperform, $50 target at Cowen
10/11/21 BofA
Procept BioRobotics initiated with a Buy at BofA
10/11/21 BofA
Procept BioRobotics initiated with a Buy at BofA
CTKB Cytek Biosciences
$10.95 /

+0.19 (+1.77%)

05/15/22 Piper Sandler
Cytek Biosciences price target lowered to $12 from $17 at Piper Sandler
03/01/22 Piper Sandler
Cytek Biosciences price target lowered to $17 from $20 at Piper Sandler
01/05/22 Piper Sandler
Cytek Biosciences assumed with an Overweight at Piper Sandler
10/14/21 Cowen
Cytek Biosciences coverage transferred at Cowen
CVRX CVRx
$6.76 /

+0.675 (+11.10%)

02/16/22 Piper Sandler
CVRx pullback brings 'excellent entry point,' says Piper Sandler
01/14/22 Piper Sandler
Piper tells small cap investors to buy basket of recent med tech IPOs
01/13/22 Canaccord
CVRx price target lowered to $17 from $30 at Canaccord
09/14/21 Piper Sandler
CMS full repeal proposal of MCIT negative for med tech, says Piper Sandler
FDT Federal Trust Corporation
$56.23 /

+0.53 (+0.95%)

FANH Fanhua
$4.78 /

+0.08 (+1.70%)

PRCT Procept BioRobotics
$38.81 /

-1.29 (-3.22%)

ERAS Erasca
$5.72 /

+0.23 (+4.19%)

DNAY Codex DNA
$3.65 /

+0.05 (+1.39%)

CVRX CVRx
$6.76 /

+0.675 (+11.10%)

CTKB Cytek Biosciences
$10.95 /

+0.19 (+1.77%)

CMAX CareMax
$5.17 /

-0.38 (-6.85%)

AIP Arteris IP
$8.98 /

-0.045 (-0.50%)

  • 27
    Oct
  • 15
    Sep
  • 23
    Jul
  • 16
    Jul
  • 30
    Jun
  • 18
    Jun
PRCT Procept BioRobotics
$38.81 /

-1.29 (-3.22%)

DNAY Codex DNA
$3.65 /

+0.05 (+1.39%)

CTKB Cytek Biosciences
$10.95 /

+0.19 (+1.77%)

CMAX CareMax
$5.17 /

-0.38 (-6.85%)

Over a quarter ago
Hot Stocks
Fanhua appoints Lichong Liu as COO, Jun Li as CDO » 17:17
03/28/22
03/28
17:17
03/28/22
17:17
FANH

Fanhua

$7.06 /

-0.13 (-1.81%)

The board of directors of…

The board of directors of Fanhua announced that Lichong Liu has been appointed as the vice president and chief operating officer, or COO, of the company to oversee corporate operations, and that Jun Li has been appointed as the vice president and chief digital officer, or CDO, of the company to accelerate the company's digital transformation, effective immediately. Lichong Liu joined Fanhua in 2006. Jun Li has worked with Fanhua since 2008.

ShowHide Related Items >><<
FANH Fanhua
$7.06 /

-0.13 (-1.81%)

Hot Stocks
Fanhua trading resumes  09:01
12/16/21
12/16
09:01
12/16/21
09:01
FANH

Fanhua

$8.91 /

-0.79 (-8.14%)

 
ShowHide Related Items >><<
FANH Fanhua
$8.91 /

-0.79 (-8.14%)

FANH Fanhua
$8.91 /

-0.79 (-8.14%)

Hot Stocks
Fanhua appoints Yinan Hu as chairman, CEO » 08:38
12/16/21
12/16
08:38
12/16/21
08:38
FANH

Fanhua

$8.91 /

-0.79 (-8.14%)

The board of directors of…

The board of directors of Fanhua announced that with immediate effect, Mr. Yinan Hu, founder and a director of the Company, has been appointed by the Company's Board to be its chairman and chief executive officer, filling the vacancy left by the resignation of Mr. Chunlin Wang. Mr. Wang has informed the Board that his resignation is due to his personal reasons. As the founder of Fanhua, Mr. Yinan Hu is also the largest shareholder of the Company, currently beneficially owns approximately 18.6% of the Company's outstanding ordinary shares.

ShowHide Related Items >><<
FANH Fanhua
$8.91 /

-0.79 (-8.14%)

FANH Fanhua
$8.91 /

-0.79 (-8.14%)

Hot Stocks
Fanhua announces receipt of non-binding going private proposal » 08:25
12/16/21
12/16
08:25
12/16/21
08:25
FANH

Fanhua

$8.91 /

-0.79 (-8.14%)

Fanhua announced that its…

Fanhua announced that its Board of Directors has received a preliminary non-binding proposal letter dated December 16, 2021, from a consortium led by Mr. Yinan Hu, founder and a director of the Company, to acquire all of the outstanding ordinary shares of the Company not already owned by the Consortium for $9.8 per American Depositary Shares, or $0.49 per ordinary share in a going private transaction, subject to certain conditions. The price represents a premium of approximately 10.2% to the closing price of the Company's ADS on December 15, 2021. Mr. Hu currently beneficially owns approximately 18.6% of the Company's outstanding ordinary shares. According to the proposal letter, Mr. Yinan Hu will form an acquisition vehicle for the purpose of implementing the Proposed Transaction, which may admit other existing shareholders of the Company and equity investors as consortium members and the acquisition is intended to be financed by a combination of debt and/or equity capital from the Potential Consortium Members. The Board intends to form a special committee consisting of independent directors to consider the Proposed Transaction. The Board of Directors cautions the Company's shareholders and others considering trading in its securities that no decisions have been made with respect to the Company's response to the proposal. There can be no assurance that any definitive offer will be made, that any agreement will be executed or that this or any other transaction will be approved or consummated. The Company does not undertake any obligation to provide any updates with respect to this or any other transaction, except as required by applicable law.

ShowHide Related Items >><<
FANH Fanhua
$8.91 /

-0.79 (-8.14%)

FANH Fanhua
$8.91 /

-0.79 (-8.14%)

Hot Stocks
Fanhua trading halted, news pending  08:23
12/16/21
12/16
08:23
12/16/21
08:23
FANH

Fanhua

$8.91 /

-0.79 (-8.14%)

 
ShowHide Related Items >><<
FANH Fanhua
$8.91 /

-0.79 (-8.14%)

FANH Fanhua
$8.91 /

-0.79 (-8.14%)

Hot Stocks
Fanhua reports total regular life insurance business exceeds RMB 10B » 05:28
11/23/21
11/23
05:28
11/23/21
05:28
FANH

Fanhua

$14.14 /

-0.16 (-1.12%)

Fanhua announced that as…

Fanhua announced that as of November 23, the total regular life insurance business facilitated by Fanhua has exceeded RMB 10B in terms of gross written premiums, over a month earlier than last year.

ShowHide Related Items >><<
FANH Fanhua
$14.14 /

-0.16 (-1.12%)

FANH Fanhua
$14.14 /

-0.16 (-1.12%)

Hot Stocks
Fanhua launches customized critical illness insurance with Greatwall » 09:03
10/26/21
10/26
09:03
10/26/21
09:03
FANH

Fanhua

$13.58 /

+0.33 (+2.49%)

Fanhua announced that it…

Fanhua announced that it has partnered with Greatwall Life Insurance to launch "Huacheng Guardian Number One", a critical illness product custom-designed to meet people's evolving needs for comprehensive health protection. The product will be sold exclusively through Fanhua's online and offline channels starting from November 1, 2021. Huacheng Guardian Number One covers 168 kinds of minor, moderate and critical illnesses, terminal illnesses and provides death benefits. In addition, Huacheng Guardian Number One provides customers with "all-round" services throughout early, middle and late stages of diseases, including, among others, multidisciplinary consultation services for tumor treatment, green channels for hospital visits, doctor's consultation on phone, advance payment for hospitalization and in-hospital nursing. Chunlin Wang, chairman and chief executive officer of Fanhua, stated, "Huacheng Guardian Number One is the result of the joint efforts of Fanhua and Greatwall Life to develop tailor-made products in response to customers' needs. It is also aligned with our commitment to building Fanhua's own product ecosystem through product customization and making it part of our core competitive advantages. I believe this product will be well received by the market and contribute to business growth for both Fanhua and Greatwall Life."

ShowHide Related Items >><<
FANH Fanhua
$13.58 /

+0.33 (+2.49%)

FANH Fanhua
$13.58 /

+0.33 (+2.49%)

Earnings
Fanhua reports Q2 EPS per ADS 19c, one estimate 17c » 17:10
08/23/21
08/23
17:10
08/23/21
17:10
FANH

Fanhua

$13.91 /

-0.59 (-4.07%)

Reports Q2 revenue…

Reports Q2 revenue $106.855M. "The resurgences of COVID-19 have brought far-reaching impact on China's economy and business activities nation-wide, directly or indirectly hurting consumer confidence and purchasing power of middle-class families. Many industries have been drastically impacted, and the insurance industry was certainly not immune." Commenting on the financial results of second quarter of 2021, Chunlin Wang, chairman and CEO, stated, "In the Q2, China's life insurance industry saw a decline of 16.6% year-over-year. Against the headwind, we still managed to record RMB2.5B in total life insurance GWP, up by 4.9% year-over-year, with operating income beating expectation to achieve RMB51.0M. For the first half of 2021, while the life insurance industry only grew by 0.4% year-over-year in GWP, our life insurance business grew by 16.9% year-over-year to RMB5.5B in terms of GWP and our operating income achieved RMB191.4M, meeting nearly two-thirds of our target for 2021.

ShowHide Related Items >><<
FANH Fanhua
$13.91 /

-0.59 (-4.07%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.